Your browser doesn't support javascript.
loading
Epidemiological survey of haemophiliacs with inhibitors in France: orthopaedic status, quality of life and cost--the 'Statut Orthopédique des Patients Hémophiles' avec Inhibiteur study.
Stieltjes, Natalie; Torchet, Marie F; Misrahi, Laure; Roussel-Robert, Valérie; Lambert, Thierry; Guérois, Claude; Bertrand, Marie A; Briquel, Marie E; Borel-Derlon, Annie; Dirat, Gérard.
Afiliação
  • Stieltjes N; Centre des hémophiles, Hôpital Cochin, Paris, France. natalie.stieltjes@cch.aphp.fr
Blood Coagul Fibrinolysis ; 20(1): 4-11, 2009 Jan.
Article em En | MEDLINE | ID: mdl-20527720
ABSTRACT
The physical condition of severe haemophilia and the impact of advances in replacement therapy have been much studied, but little work has been done on patients who developed inhibitors. The 'Statut Orthopédique des Patients Hémophiles avec Inhibiteur' study was conducted in France in order to assess the orthopaedic status and quality of life of such patients, and the cost of their medical management. Fifty haemophiliacs aged 12-63 years with a history of high-responder inhibitors were included. Clinical assessment showed that only 12% of the patients had a nil pain score and 2% a nil clinical score, as per Gilbert scale. The mean clinical score was significantly higher in patients over 35 years of age than in younger ones. However, younger patients appeared to have a more impaired orthopaedic status than young haemophiliacs without inhibitors of similar age in previous published cohorts. Surprisingly, older haemophiliacs tended to have the best mental quality of life, contrasting with their highly impaired orthopaedic condition and physical quality of life. The mean cost of clinical resources consumed during the year preceding enrolment was Euro 268 999, 99% of which was related to clotting factor. Marked between-patient differences in cost were noted. Our study suggests that the management of haemophiliacs with inhibitors should be improved in order to prevent haemophilic arthropathy to an extent similar to that of patients without inhibitors. Cost-benefit assessment of any therapeutic strategy should always be combined with quality-of-life evaluation.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Hemofilia B / Custos de Cuidados de Saúde / Hemofilia A Tipo de estudo: Health_economic_evaluation / Observational_studies / Prevalence_studies / Risk_factors_studies Aspecto: Patient_preference Limite: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Blood Coagul Fibrinolysis Assunto da revista: ANGIOLOGIA / HEMATOLOGIA Ano de publicação: 2009 Tipo de documento: Article País de afiliação: França
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Hemofilia B / Custos de Cuidados de Saúde / Hemofilia A Tipo de estudo: Health_economic_evaluation / Observational_studies / Prevalence_studies / Risk_factors_studies Aspecto: Patient_preference Limite: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Blood Coagul Fibrinolysis Assunto da revista: ANGIOLOGIA / HEMATOLOGIA Ano de publicação: 2009 Tipo de documento: Article País de afiliação: França